Andrew Evens, DO, MBA, FACP, Rutgers University, New Brunswick, NJ, shares some insights into treatment strategies for older and frail patients with Hodgkin lymphoma (HL), and challenges in this space. Dr Evens first explain factors that influence patient response to therapy, and why older patients may not respond as well as younger patients. Following this, Dr Evens comments on how the incorporation of geriatric assessments may improve outcomes for patients, and concludes by discussing the benefits observed with the use of novel targeted agents, such as brentuximab vedotin. This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Grant/Research Support: ORIEN and Leukemia & Lymphoma Society, Advisory Board (Research Related): Seattle Genetics, Hutchmed, Incyte, Daiichi Sankyo, and Epizyme Consultant (Educational Related): Research to Practice, Curio, Cota, Patient Power, Curio Science, and OncLive Consultant (Data and Safety Monitoring Board): Novartis, Abbvie, and Pharmacyclics